WallStSmart

Edwards Lifesciences Corp (EW)vsENvue Medical Inc. (FEED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 288919% more annual revenue ($6.30B vs $2.18M). EW leads profitability with a 17.4% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 59/100 (C).

EW

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 8.0Value: 6.0Quality: 8.5
Piotroski: 3/9Altman Z: 4.48

FEED

Avoid

30

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 2/9Altman Z: -1.85
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWUndervalued (+68.5%)

Margin of Safety

+68.5%

Fair Value

$251.46

Current Price

$94.37

$157.09 discount

UndervaluedFair: $251.46Overvalued

Intrinsic value data unavailable for FEED.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW5 strengths · Avg: 9.4/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Market CapQuality
$51.66B9/10

Large-cap with strong market position

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

FEED2 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.154/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
48.5x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-21.10M2/10

Negative free cash flow — burning cash

FEED4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$3.14M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bull Case : FEED

The strongest argument for FEED centers on Price/Book, Debt/Equity.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 48.5x leaves little room for execution misses.

Bear Case : FEED

The primary concerns for FEED are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

EW profiles as a growth stock while FEED is a value play — different risk/reward profiles.

FEED carries more volatility with a beta of 1.50 — expect wider price swings.

EW is growing revenue faster at 16.7% — sustainability is the question.

FEED generates stronger free cash flow (-4M), providing more financial flexibility.

Bottom Line

EW scores higher overall (59/100 vs 30/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

ENvue Medical Inc.

HEALTHCARE · MEDICAL DEVICES · USA

ENvue Medical Inc. (FEED) is an innovative healthcare technology company dedicated to enhancing patient care management through cutting-edge medical devices and integrated software solutions. By leveraging advanced technology, ENvue aims to streamline recovery processes and optimize health outcomes across diverse clinical environments. With a strong pipeline of products and strategic partnerships, the company is well-equipped to capitalize on the expanding opportunities in the healthcare sector, making it an attractive investment prospect for institutional investors interested in the evolution of medical devices and digital health innovations.

Want to dig deeper into these stocks?